In addition, patients on SGLT2 inhibitors to control their T2DM experience a reduction in insulin resistance, as measured by HOMA-IR, as well as a mild increase in circulating ketone bodies [8,9,10]. This evidence concerns the gene SLC5A2 and Insulin resistance.